SCHEMBL13608955

SCHEMBL13608955

CCOC(=O)N1CCC2(CC1)OCC(CC)(CC)O2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
RECQL P46063 1/20 0.42
POLB P06746 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ALDH1A1 P00352 7/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.38
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.37
MAPT P10636 2/20 0.36
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13609306 0.90 CYP2D6 (0.42) TSHRALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL13609234 0.84 KMT2A (0.39) TSHRL3MBTL1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13609235 0.83 MEN1 (0.52) L3MBTL1ALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL13609315 0.78 KMT2A (0.50) TSHRPOLBL3MBTL1ALDH1A1HTT
SCHEMBL8188669 0.76 TSHR (0.55) TSHRRECQLPOLBL3MBTL1ALDH1A1
SCHEMBL5023611 0.73 POLB (0.55) TSHRRECQLPOLBL3MBTL1ALDH1A1
SCHEMBL5986980 0.72 TSHR (0.53) TSHRRECQLPOLBL3MBTL1ALDH1A1
SCHEMBL13618589 0.72 POLB (0.51) TSHRRECQLPOLBL3MBTL1ALDH1A1
SCHEMBL12086321 0.71 TSHR (0.52) TSHRRECQLPOLBL3MBTL1ALDH1A1
SCHEMBL13609309 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291923-A1 TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES JOHNS HOPKINS UNIVERSOTY (US) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291923-A1 TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES HCCS, XPO5, DHX15 TSHR 3979/4885RECQL 84/4885POLB 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.